Pathogen Inactivation of Labile Blood Products: Blood Transfusion and Histocompatibility, Page 296
Council of Europe
Council of Europe Publ., 2001 - Medical - 75 pages
Methods aimed at inactivation of pathogens in labile blood products have been developed in recent years. Their use raises a number of issues, including efficiency, the damage inflicted to the blood products, the toxicity for patients, and the cost-benefit ratio. In the foreseeable future, national blood transfusion services and health authorities will have to consider the introduction of these methods. The report summarises the current information on these pathogen inactivation procedures.
What people are saying - Write a review
We haven't found any reviews in the usual places.
CLINICAL USE AND EXPERIENCE
4 other sections not shown
Other editions - View all
activation affinity for nucleic assays assessment autologous bacteria Bacterial contamination blood cell concentrates blood components blood transfusion blood transfusion services BVDV cell-associated cell-free cell-free/cell-assoc cellular blood products clinical trials coagulation factors compounds cost-effectiveness Creutzfeldt-Jakob disease damage DHBV disease donor effect erythrocytes FRALEs fresh frozen plasma GVHD hepatitis human inactivation of labile infections labile blood products leukocyte depletion leukocytes lymphocytes Margolis-Nunno H mechanisms of action methylene blue model viruses non-enveloped viruses nucleic acids parvovirus B19 pathogen inactivation procedures patients phase photochemical reaction photochemical treatment photodynamic reactions photoinactivation photosensitiser phthalocyanines plasma proteins platelet platelet concentrates platelet function psoralen psoralen S-59 quenchers reactive oxygen species Recommendation recovery red blood cell red cells reduced risk S-59 treated safety sensitiser singlet oxygen solvent/detergent storage studies substrate target Transfusion Medicine transfusion-associated transfusion-transmitted transmission treated FFP ultraviolet viral virus inactivation visible light vivo Vox Sang